All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Evangelos Terpos, National and Kapodistrian University of Athens, Athens, GR. He discusses what you need to know about keratopathy management with belamaf.
What you need to know about keratopathy management with belamaf
Belamaf is an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) approved in the US and EU for the treatment of relapsed/refractory multiple myeloma (R/R MM). Terpos outlines a study investigating the relationships between corneal exam findings, best-corrected visual acuity (BCVA) changes, and patient-reported ocular symptoms in patients with R/R MM receiving belamaf.
Dose-escalation study of ABBV-838, an antibody–drug conjugate, in patients with relapsed and refractory multiple myeloma
A first-in-human study investigating the safety profile, pharmacokinetics, and preliminary activity of ABBV-838, in patients with...
Primary objective met in the DREAMM-2 trial of belantamab mafodotin in relapsed/refractory multiple myeloma
On 23rd August 2019, headline results from the pivotal DREAMM-2 open-label, two-arm, randomized, phase II study of belantamab mafodotin...
Subscribe to get the best content related to multiple myeloma delivered to your inbox